Neoleukin Therapeutics

$13.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.34 (+2.62%) Today

$0.00 (0.00%) As of 11:02 AM UTC after-hours

Why Robinhood?

You can buy or sell NLTX and other stocks, options, and ETFs commission-free!

About NLTX

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. The listed name for NLTX is Neoleukin Therapeutics, Inc. Common Stock.

CEO

Jonathan G. Drachman

Employees

Headquarters

Seattle, Washington

Founded

2003

Market Cap

585.23M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

412.75K

High Today

$13.39

Low Today

$12.80

Open Price

$12.86

Volume

251.64K

52 Week High

$18.13

52 Week Low

$5.81

Collections

Analyst Ratings

100%

of 7 ratings

Buy

100%

Hold

Sell

NLTX Earnings

-$0.44

-$0.29

-$0.15

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 11, Pre-Market